Posts Archive

NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies RRMM Study Assessing Activity of Intravenous (IV)...

EMN 29 NCT05028348: Phase 3: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide,...

NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With...

ClaSPd NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed...

SABLe NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients...

Multiple Myeloma Research Consortium MyDRUG RRMM NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG) Multiple...

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222: Phase 2: SELIBORDARA:...

BOSTON Study This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and...

STORM Selinexor Treatment of Refractory Myeloma (STORM) This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg...

STOMP Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP) This study will independently assess the efficacy and safety...

Multiple Myeloma Research Consortium NCT02199665: Phase 1: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed...